Ticker Details
Ovid Therapeutics Inc. Ovid Therapeutics Inc is a US-based biopharmaceutical company. The firm is engaged primarily in developing medicines for patients suffering with rare neurological disorders.
IPO Date:	May 10, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$485.26M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 3.87%
Avg Daily Range (30 D):	$0.09 | 3.89%
Avg Daily Range (90 D):	$0.10 | 4.01%

Institutional Daily Volume
Avg Daily Volume:	.68M
Avg Daily Volume (30 D):	2.06M
Avg Daily Volume (90 D):	2.69M

Trade Size
Avg Trade Size (Sh.):	218
Avg Trade Size (Sh.) (30 D):	131
Avg Trade Size (Sh.) (90 D):	171

Institutional Trades
Total Institutional Trades:	156
Avg Institutional Trade:	$2.27M
Avg Institutional Trade (30 D):	$3.97M
Avg Institutional Trade (90 D):	$2.75M
Avg Institutional Trade Volume:	.71M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.69M
Avg Closing Trade (30 D):	$5.41M
Avg Closing Trade (90 D):	$4.2M
Avg Closing Volume:	1.11M

News

Mar 18, 2026 @ 6:17 PM Here's Why Ovid Therapeutics Stock Popped Higher T... Source: Lee Samaha

Mar 18, 2026 @ 10:00 AM Ovid Therapeutics Announces Pricing of $60 Million... Source: Na

Nov 12, 2025 @ 12:00 PM Ovid Therapeutics Announces Planned Leadership Suc... Source: Ovid Therapeutics

Feb 27, 2025 @ 1:00 PM Ovid Therapeutics to Present at the TD Cowen 45th ... Source: N/A

Feb 20, 2025 @ 6:00 PM Epilepsy Market Assessment in the 7MM by 2034 ââ‚... Source: Delveinsight

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS
Diluted EPS
Revenue	$7.12M	$M	$.72M
Gross Profit
Net Income / Loss	$-24.17M	$-16.99M	$9.66M
Operating Income / Loss	$-47.74M	$-17.85M	$-12.29M
Cost of Revenue
Net Cash Flow	$73.22M	$81.03M	$-7.29M
PE Ratio